This guide aims to help you address some likely questions and prepare you for your first appointment with a lung cancer specialist - learn more.
Tycel Phillips, MD, discusses the impact of the recent approval of subcutaneous epcoritamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.Video Player is loading.This is a modal window. ...
“This international survey helps to bring the current advanced lung cancer treatment landscape into the spotlight, and interestingly track what has and hasn’t changed in the last year,” said Dr. Matthew Peters, Chair of the Global Lung Cancer Coalition (GLCC). “These patients can benefit f...
Toni Choueiri, MD:Well, the field is changing at a rapid pace in RCC, and first in metastatic renal cell cancer, kidney cancer. So, we had, for the past 10 to 15 years, targeted agentsusually oral agents, drugs that target the VEGF receptor—and mTOR inhibitors. And for the...
For each drug, we used FDA-approved drug labels to identify the relevant cancer indications, defined as a combination of cancer type and line of therapy (eg, first-line treatment of advanced breast cancer). Approval dates for each drug-indication pair were checked against those listed in the ...
e18857#Background:Consolidation durvalumab is approved for treatment of newly diagnosed, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed after definitive chemoradiotherapy (CRT) and the NCCN guidelines has since included stage II NSCLC who have not progressed after ...
Homocysteine levels in newly diagnosed patients with non-small cell lung cancer 来自 ResearchGate 喜欢 0 阅读量: 19 作者:J Maguire,A Armour,V Kelly,M Ledson,M Walshaw 摘要: Concurrent chemoradiation is an effective form of treatment for inoperable stage 3 NSCLC, with a survival advantage in ...
Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and tria... The aim of this study is to evaluate the efficacy and safety of faecal microbiota transplantation (FMT) for the treatment of irritable bowel...
Cancer Drugs and Indications Newly Approved By U.S. Food and Drug Administration, May 2005 – April 2007 Anastrozole (Arimidex): Conversion to regular approval for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. Issued September 2005. Bevacizumab (Avas...
On July 30, 2024, the FDA approved thedaratumumab and hyaluronidase-fihj regimen(Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous ...